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Abstract
Mice lacking GPR103A expression display osteopenia. Analysis of mouse quantitative trait loci literature associated with bone mineral density
suggested GPR103A ligand P518/Qrfp (chromosome 2qB) as a candidate osteoporosis gene. Promoter and coding regions of mouse P518/Qrfp
were sequenced from genomic DNA obtained from the osteoporosis-prone strain SAMP6 and control strains SAMR1, A/J, AKR/J, BALB/c,
C3H/HeJ, C57BL/6J, and DBA/2J. Four single-nucleotide polymorphisms (SNPs) were identified in only SAMP6 genomic DNA, g.−1773
T→C, g.110 A→G (N37S), g.188 G→A (R63K), and g.135 T→C (H45H). The promoter SNP generated a novel neuron-restrictive silencing
factor binding site, a repressor that decreases gene expression in nonneuronal tissues. TaqMan analysis demonstrated fivefold lower P518/Qrfp
liver expression in SAMP6 versus SAMR1 or C57BL/6J control strains. Tissue distribution of human, mouse, and rat P518/Qrfp and its receptors
showed expression in bone and spinal cord. A direct role for P518/Qrfp function in maintaining bone mineral density is suggested.
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nine–phenylalanine amide of length 26 amino acids) and
QRFP-26 (pyroglutamyl–arginine–phenylalanine amide of
length 26 amino acids)) as an RFamide (arginine–phenylalanine
amide) peptide agonist ligand of the G-protein-coupled receptor
SP9155 (a.k.a. GPR103 and AQ27) has been previously
reported [1]. Several subsequent studies have identified
biological roles for P518/Qrfp and its receptor. Intracerebro-
ventricular (icv) administration of P518/Qrfp was demonstrated
to be orexigenic in partially food-deprived mice [2] and 13-day
chronic icv administration of a longer form, QRFP-43, caused
obesity (15% weight gain), hyperphagia, decreased expression
of brown adipose uncoupling protein-1, and reduced thermo-
genesis [3]. QRFP-43 regulates appetite and energy expenditure⁎ Corresponding author. Fax: +1 908 740 7664.
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doi:10.1016/j.ygeno.2007.07.011in mice. Additionally, P518/Qrfp acts as an endocrine hormone:
Intravenous administration of QRFP-43 to rats results in
elevated levels of aldosterone [4]. Administration of a shorter
form, P52, or P518/Qrfp or QRFP-43 enhances basal or GnRH-
stimulated LH secretion from pituitary in rats, and icv
administration of P52, P518/Qrfp, or QRFP-43 to rats invokes
increased serum LH in normal and ovariectomized rats [5].
Intracerebroventricular QRFP-43 administration in mice
induces feeding, increased general locomotor activity, increased
blood pressure, increased heart rate, and increased metabolic
rate [6]. Recently, intravenous administration of P518/Qrfp to
rats has been demonstrated to inhibit glucose-stimulated insulin
release in pancreas [7]. P518/Qrfp induces both feeding and
locomotor activity on icv administration in mice but the feeding
activity is centered in the C-terminus of this RFamide and the
locomotor activity resides in the N-terminus [8]. The central
portion of the P518/Qrfp peptide adopts a helical structure in
solution [9]. Extensive analysis of the completed human
genome sequence has identified only one isoform of the
630 Q. Zhang et al. / Genomics 90 (2007) 629–635P518/Qrfp receptor. However, two rodent orthologs of the
human P518/Qrfp receptor GPR103 have been identified that
are similar with regard to sequence, response to P518/Qrfp, and
tissue distribution [6,10].
Genetically engineered mice lacking GPR103A expression
displayed osteopenia, suggesting a role for GPR103A and/or its
ligand in bone formation [11]. We searched for quantitative trait
loci (QTL) associated with bone mineral density within 5 Mb of
the genomic regions encoding the human, mouse, and rat P518/
Qrfp ligand (a.k.a. RF26a and QRFP-43) and its receptor
GPR103A using a novel tool we have recently developed for
mapping phenotype literature to genomic regions (Q. Zhang,
manuscript in preparation). Interestingly, two independently
performed, genome-wide scans had mapped a chromosome 2
locus associated with bone mineral density [12,13], but had not
been resolved to a single gene. P518/Qrfp maps within the
critical region of both scans. One of the studies identified this
region by comparing SAMP6 and SAMR1 control mice, as well
as by comparing SAMP6 mice to the parent strain AKR/J.
SAMP mouse strains were developed by extensive inbreeding
of AKR/J mice; the SAMP6 strain demonstrates marked
osteopenia [12]. We rationalized that polymorphisms in
mouse P518/Qrfp could be associated with altered ligand
level and/or protein sequence and sought to identify strain-
associated single-nucleotide polymorphisms (SNPs) in theFig. 1. Map of 3.875-Mb mouse chromosome 2 bone mineral density-associated locu
are from the mm8 mouse genome assembly of February 2006, Chr2 base pairs 27,6
Browser [26,27].inbred senescent mouse strain SAMP6. We also examined the
expression and distribution of GPR103A, GPR103B, and P518/
Qrfp precursor in humans and rodents and liver expression of
P518/Qrfp in the SAMP6 and SAMR1 mouse strains.
Results
A prior QTL study on SAMP6×AKR/J and SAMP6×
SAMR1 crosses identified a mouse chromosome 2qB locus
associated with bone mineral density between the type V
collagen 5α1 and the prostaglandin G/H synthase 1 (Ptgs1,
a.k.a. COX1) genes [12]. The P518/Qrfp precursor is located
in the center of this locus (Fig. 1). P518/Qrfp was not
considered as a candidate gene at the time of the QTL study
as the study predated P518/Qrfp identification [1].
Variations were found only in DNA isolated from SAMP6
mice; all other mouse strains had the same sequence, including
control strains SAMR1 and AKR/J (from which SAMR1 and
SAMP6 were derived) and the strains A/J, BALB/c, C3H.HeJ,
C57BL/6J, and DBA/2J. The four SNPs identified were
g.−1773 T→C in the promoter region; two coding SNPs,
g.110 A→G (N37S) and g.188 G→A (R63K); and one silent
SNP, g.135 T→C (H45H). A schematic map of the SNPs
associated with the genomic sequence is provided (Fig. 2). Since
the two coding SNPs changed the protein coding sequence tos [12]. Boundary genes Col5a1, Ptgs1, and P518/Qrfp boxed in red. Coordinates
90,000–36,075,000. Graphic is a snapshot generated with the UCSC Genome
Fig. 3. Expression of P518/Qrfp in mouse liver. Expression values are plotted as
the average and standard deviation for three animals/strain.
Fig. 2. (A) SAMP6 P518/Qrfp SNPs mapped to genomics structure and (B) P518/Qrfp protein sequences (numbering is that of mouse P518/Qrfp). Nomenclature is
according to the Human Genome Variation Society recommendations [28]. NRSF, TATA promoter elements, exon boundaries, and coding regions are indicated above
the diagram. Reference mRNA for exon structure is GenBank entry NM_183424.1 and those for protein sequences are NP_906269.1, NP_937843.1, and
NP_937823.1 for mouse, rat and human P518/Qrfp, respectively.
631Q. Zhang et al. / Genomics 90 (2007) 629–635their rat residue counterparts and since both residues were
upstream of known biologically active peptide fragments in the
message, we focused on the g.−1773 T→C SNP.
Promotor region analysis was performed using a TRANS-
FAC database search with the MATCH program [14,15]. A
transcription factor binding site was identified for neuron-
restrictive silencing factor (a.k.a. NRSF and RE1-silencing
transcription factor, or REST) that matched TRANSFAC Entry
M00256. The NRSF consensus pattern is a 21-mer, TTCAG-
CACCACGGACAGMGSC, that matched SAMP6 P518/Qrfp
g.−1787:g.−1767, TGCAGCAcagagagcatcatc [16]. The 15th
position of the pattern in known NRSF binding sites is C and
infrequently G. The SAMP6 g.−1773 T→C SNP generates an
improved NRSF binding site match in the mouse P518/Qrfp
promoter. NRSF represses transcription of neuronal genes in
nonneuronal cells, including the GPCR peptide ligand
precursors for CRF and proenkephalin [17]. Thus, the −1773
T→G SNP could result in lower expression of P518/Qrfp in
nonneuronal tissues in osteopenic SAMP6 mice, consistent
with the decrease in bone mineral density seen in GPR103A
receptor knockouts. We therefore measured the expression
level of P518/Qrfp in mRNA isolated from SAMP6 and
SAMR1. Measurement of P518/Qrfp mRNA by TaqMan
analysis demonstrated that liver levels of P518/Qrfp message
were reduced fivefold in SAMP6 mice (Fig. 3).
TaqMan analysis of tissue expression of P518/Qrfp and its
receptor(s) in human, mouse, and rat was also performed. Little
if any GPR103A or GPR103B receptor was observed in mouseliver, but message for P518/Qrfp was present (Fig. 4A).
Surprisingly, rat GPR103A and GPR103B distribution was
quite similar, unlike that observed for the mouse receptors (Figs.
4A and 4B). Prior studies had shown higher expression of
mouse GPR103B in testis and eye [6] and expression of mouse
GPR103A in eye and spine and human GPR103 in bone and
heart [11]. We saw expression of mouse P518/Qrfp in bone and
632 Q. Zhang et al. / Genomics 90 (2007) 629–635higher expression of GPR103A than GPR103B in retina (Fig.
4A). Human GPR103 was also expressed in retina and heart
(Fig. 4C). We also observed expression of human GPR103,
mouse GPR103A and GPR103B, and rat GPR103A and
GPR103B in spinal cord (Figs. 4A–4C) and mouse
GPR103A and GPR103B in bone (Fig. 4A). During final
preparation of this article, a report was published characterizing
expression of rat P518/Qrfp and GPR103A and GPR103B in
brain by in situ hybridization, showing message for P518/Qrfp
in hypothalamus and GPR103B in thalamus and brain stem
[18], and a report appeared demonstrating expression of human
P518/Qrfp in brain and spinal cord [19], consistent with our
findings.
We examined the expression of P518/Qrfp, GPR103A, and
GPR103B in SAMP6 and SAMR1 in additional tissues
including lumbar spine, brain, hypothalamus, heart, and kidney
(Fig. 5). Peripheral expression of P518/Qrfp is reduced in
SAMP6 lumbar spine, which is significant because this is the
site of the phenotype observed in GPR103A knockout mice
[11]. GPR103A and GPR103B expression was similar in
lumbar spine. We also observed that P518/Qrfp expression is
reduced in SAMP6 brain and hypothalamus. GPR103A and
GPR103B expression is increased in SAMP6 heart.Fig. 4. Expression of P518/Qrfp and receptor(s). (A) Mouse P518/Qrfp and GPR1
and GPR103.Discussion
Several genomic loci have been associated with osteoporo-
sis, some of which have been resolved to sequence polymorph-
isms in specific genes, described in detail in a recent review
[20]. To our knowledge this is the first identification of a
molecular candidate for the mouse chromosome 2qB QTL and
the first identification of osteopenia-associated SNPs in the
P518/Qrfpmessage. Searches of public SNP data did not reveal
prior identification of the four SNPs reported in this study.
The SAMP6 osteoporosis-prone mouse strain has a SNP in
the P518/Qrfp promoter region resulting in generation of a
putative repressive transcription factor binding site correlating
with reduced peripheral expression. This coupled with observa-
tion of osteopenia in GPR103A knockout mice [11] suggests
P518/Qrfp function is important for maintaining mineral bone
density. The presence of ligand and receptor in spinal cord,
bone, and osteoblasts [11] and inverse correlation of peripheral
P518/Qrfp levels with osteopenia suggest that P518/Qrfp role
in maintaining bone mineral density is direct as opposed to
centrally mediated.
Direct proof of SAMP6 P518/Qrfp NRSF promoter function
has yet to be established. Proof might be obtained by direct binding03A and B. (B) Rat P518/Qrfp and GPR103A and B. (C) Human P518/Qrfp
Fig. 4 (continued).
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SAMP6 variant into a different strain, or characterizing
heterozygotes.
P518/Qrfp expression was also reduced in SAMP6 brain and
hypothalamus (Fig. 5). NRSF neuronal silencing has been
observed previously. NRSF silences nonneuronal expression
and its neuronal expression is developmentally regulated [16],
and it has also been shown to repress expression of mu opioid
receptor in neuronal cells [29].
Use of P518/Qrfp and/or receptor agonists may be of benefit
in osteoporosis. Presence of human GPR103 in heart (Fig. 4C)
and reported effects of QRFP-43 on blood pressure and heart
rate [6], which may be directly as opposed to centrally
mediated, should be considered as a cautionary factor.
Materials and methods
Mouse DNA and RNA samples
The promoter and coding region of P518/Qrfp were sequenced from
genomic DNA obtained from mouse strains SAMP6, SAMR1, A/J, AKR/J,
BALB/c, C3H/HeJ, C57BL/6J, and DBA/2J (n=3 per strain). Genomic DNA
was isolated from liver using the DNeasy Tissue kit (Qiagen, Valencia, CA,
USA). RNA was obtained from livers of SAMP6 and SAMR1 mice using
QIAZOL and RNeasy kits (Qiagen). Tissues from SAMP6 and SAMR1 mice
were obtained from Harlan Laboratories (Indianapolis, IN, USA, and UK).Polymerase chain reaction
The general strategy for SNP discovery was as previously described [21] with
modifications as detailed below. PCR primers were designed using the Primer3
software [22] (http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi) to
amplify the P518/Qrfp promoter and coding region. One amplicon was produced
using the forward primer 5′-CATATACCAGAACACCTCATCTGC-3′ and reverse
5′-CAGAGATTAATACTTCCTGGCTGG-3′, and the second was amplified using
the forward primer 5′-GCTACAGGTGAATAGGAATCAGAC-3′ and reverse 5′-
TAGTGCACTGTGATACTCTCTCCG-3′. Forward and reverse primers were 5′
tailed with universal sequencing primers (−21M13, 5′-TGTAAAACGACGGC-
CAGT, and M13Rev, CAGGAAACAGCTATGACC, respectively).
PCRs contained genomic DNA (24 ng) in the presence of USB FideliTaq
(USB Corp., Cleveland, OH, USA) and 0.2 pmol/μl forward and reverse primers
in 12 μl total volume. Thermocycling was performed in 96-well microplates
(PTC-200 thermocycler; MJ Research) with an initial denaturation at 94 °C for
5 min followed by 35 cycles of denaturation at 94 °C for 30 s, primer annealing
at 65 °C for 30 s, and primer extension at 68 °C for 1 min. After 35 cycles, a final
extension was carried out for 7 min at 68 °C.
DNA sequencing and analysis
Following DNA amplification, PCRs were diluted to 50 μl in PCR buffer
containing 0.5 μl of ExoSAP-IT (USB Corp.) and were incubated 15 min at
37 °C followed by inactivation of the enzymes at 80 °C for 15 min. Cycle
sequencing in the forward and reverse directions was performed using the ABI
Prism BigDye Terminator v3.1 Cycle Sequencing DNA Sequencing Kit
(Applied Biosystems (ABI), Foster City, CA, USA) according to the
manufacturer's instructions. Briefly, 1 μl of each PCR product was used as
Fig. 4 (continued).
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M13 sequencing primer (−21M13 or M13Rev), 0.5× Sequencing buffer and
BDTv3.1 mix. Sequencing reactions were denatured for 1 min at 96 °C followed
by 25 cycles at 96 °C for 10 s, 50 °C for 5 s, and 60 °C for 4 min. Sequencing
reactions were purified by filtration using Montage SEQ96 plates (Millipore
Corp., Bedford, MA, USA), dissolved in 25 μl deionized water, and resolved byFig. 5. Expression of P518/Qrfp, GPR103A, and GPR103B in SAMP6 and SAMR1
three animals/strain. *pb0.05.capillary gel electrophoresis on an Applied Biosystems 3730XL DNA analyzer.
Chromatograms were transferred to a Unix workstation (DEC alpha; Compaq
Corp), bases were called with Phred (version 0.990722.g), assembled with Phrap
version 3.01 [23,24], and scanned with PolyPhred [21], and the results were
viewed with Consed [25] version 9.0 (Phred, Phrap, and Consed available at
http://www.genome.washington.edu, PolyPhred is available at http://droog.mbt.tissues. Expression values are plotted as the average and standard deviation for
Table 1
Primer and probe sequences used in quantitative PCRs
Human Mouse Rat
P518/Qrfp
Forward GGCCTTACCCCCTGATCTACTT TCGGAGCCAGGATGAACTG GTGCCTCTGCTCTTGGCTTT
Reverse CTTCTGTCCAGTAGAGGGAAGCA CTGTGGATTTTGAACCGAGTTG GATGTCTGTGGGTCCCCTTCT
Probe TCTTCCTGCCGCTGGGCGC TGGCTGAGGGACATC CTCCTGCCTCTGAGTGCCTGC
GPR103A
Forward AGAAATGTCCAAAATAGCCAGGAAG CACCGCGGAGCAGTTTT GCACGGAAGCCTGGGAAT
Reverse GGACAACATGGAATGGTGCC TGTTCCCGAGTCAGGTTGTGT ATGTGTCTCCTTTGGTTTCTTCCA
Probe TGTCATTATGATGGTGACAGTGGTGGCTCTC CGGCTGCTGAGCG AGCAAAGTTATCTCGACCACAGCGTCCA
GPR103B
Forward N/A TTGCTATTGCATTGTGAAGGAAA TGTGATGCACAGAAGAGTGAAGTTAG
Reverse N/A CACCATAGCTCCTGAACTTCCAT TGCTGCCCCCAAATGCT
Probe N/A ACCTTCTTCAGCACGGAA TGTGGGAGAGAATCCTGTAGAGATCA
635Q. Zhang et al. / Genomics 90 (2007) 629–635washington.edu). Analysis parameters were all maintained at the individual
software's default settings. SNPs were scored only if identified in both forward
and reverse runs.
Quantitative PCR
TaqMan primers and probes were designed with Primer Express software
(ABI) and purchased from ABI. Primer and probe sequences are provided in
Table 1. Tissue preparations, assay conditions, and quantitation were as
described previously [1].
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